Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease.

Prokopienko AJ, West RE 3rd, Schrum DP, Stubbs JR, Leblond FA, Pichette V, Nolin TD.

Sci Rep. 2019 Nov 4;9(1):15901. doi: 10.1038/s41598-019-52032-9.

2.

Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate Data.

Franchetti Y, Nolin TD.

J Pharmacol Exp Ther. 2019 Oct;371(1):151-161. doi: 10.1124/jpet.119.257212. Epub 2019 Aug 9.

PMID:
31399494
3.

Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease.

Prokopienko AJ, West RE 3rd, Stubbs JR, Nolin TD.

J Pharm Biomed Anal. 2019 Sep 10;174:618-624. doi: 10.1016/j.jpba.2019.06.033. Epub 2019 Jun 24.

PMID:
31276982
4.

Engaging and Empowering Stakeholders to Advance Pharmacogenomics.

Crisamore KR, Nolin TD, Coons JC, Empey PE.

Clin Pharmacol Ther. 2019 Aug;106(2):305-308. doi: 10.1002/cpt.1470. Epub 2019 Jun 26. No abstract available.

PMID:
31241758
5.

Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Casal MA, Nolin TD, Beumer JH.

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):587-595. doi: 10.2215/CJN.11721018. Epub 2019 Mar 19.

PMID:
30890575
6.

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE 3rd, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD.

Clin J Am Soc Nephrol. 2019 Feb 7;14(2):261-267. doi: 10.2215/CJN.06190518. Epub 2019 Jan 21.

PMID:
30665924
7.

Extracorporeal treatment in salicylate poisoning.

Hoffman RS, Juurlink DN, Ghannoum M, Nolin TD, Lavergne V, Gosselin S.

Clin Toxicol (Phila). 2019 May;57(5):377-378. doi: 10.1080/15563650.2018.1517882. Epub 2018 Oct 11. No abstract available.

PMID:
30307333
8.

Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e-/- Mice.

Ramezani A, Nolin TD, Barrows IR, Serrano MG, Buck GA, Regunathan-Shenk R, West RE 3rd, Latham PS, Amdur R, Raj DS.

Sci Rep. 2018 Oct 3;8(1):14752. doi: 10.1038/s41598-018-33018-5.

9.

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM.

Clin Pharmacol Ther. 2019 Mar;105(3):719-729. doi: 10.1002/cpt.1205. Epub 2018 Oct 26.

PMID:
30074626
10.

Use of extracorporeal treatments in the management of poisonings.

Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Lavergne V, Roberts DM.

Kidney Int. 2018 Oct;94(4):682-688. doi: 10.1016/j.kint.2018.03.026. Epub 2018 Jun 27. Review.

PMID:
29958694
11.

Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice.

Johnson C, Prokopienko AJ, West RE 3rd, Nolin TD, Stubbs JR.

Drug Metab Dispos. 2018 Sep;46(9):1304-1309. doi: 10.1124/dmd.118.081646. Epub 2018 Jun 18.

PMID:
29915157
12.

Introduction to Nephropharmacology for the Clinician: A New CJASN Series.

Nolin TD, Perazella MA.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1083-1084. doi: 10.2215/CJN.03180318. Epub 2018 Apr 16. No abstract available.

13.

Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning.

Hudson JQ, Nolin TD.

Adv Chronic Kidney Dis. 2018 Jan;25(1):14-20. doi: 10.1053/j.ackd.2017.10.003. Review.

PMID:
29499882
14.

Activation of Constitutive Androstane Receptor Ameliorates Renal Ischemia-Reperfusion-Induced Kidney and Liver Injury.

Choi YJ, Zhou D, Barbosa ACS, Niu Y, Guan X, Xu M, Ren S, Nolin TD, Liu Y, Xie W.

Mol Pharmacol. 2018 Mar;93(3):239-250. doi: 10.1124/mol.117.111146. Epub 2018 Jan 19.

15.

Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies.

Roumelioti ME, Trietley G, Nolin TD, Ng YH, Xu Z, Alaini A, Figueroa R, Unruh ML, Argyropoulos CP.

Nephrol Dial Transplant. 2018 Mar 1;33(3):542. doi: 10.1093/ndt/gfx373. No abstract available.

PMID:
29329421
16.

Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.

Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F.

Kidney Int Rep. 2017 Jun 8;2(6):1050-1058. doi: 10.1016/j.ekir.2017.06.002. eCollection 2017 Nov.

17.

Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies.

Roumelioti ME, Trietley G, Nolin TD, Ng YH, Xu Z, Alaini A, Figueroa R, Unruh ML, Argyropoulos CP.

Nephrol Dial Transplant. 2018 Jun 1;33(6):1025-1039. doi: 10.1093/ndt/gfx311. Erratum in: Nephrol Dial Transplant. 2018 Mar 1;33(3):542.

PMID:
29186592
18.

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM.

Clin Pharmacol Ther. 2018 May;103(5):854-867. doi: 10.1002/cpt.807. Epub 2017 Oct 9.

19.

Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Prokopienko AJ, Nolin TD.

Expert Rev Clin Pharmacol. 2018 Jan;11(1):71-82. doi: 10.1080/17512433.2018.1378095. Epub 2017 Sep 20. Review.

20.

Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children.

Clark RSB, Empey PE, Bayır H, Rosario BL, Poloyac SM, Kochanek PM, Nolin TD, Au AK, Horvat CM, Wisniewski SR, Bell MJ.

PLoS One. 2017 Jul 7;12(7):e0180280. doi: 10.1371/journal.pone.0180280. eCollection 2017.

21.

Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud.

Nolin TD.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2101-2103. Epub 2016 Nov 28. No abstract available.

22.

Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine.

Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, Empey PE.

Xenobiotica. 2017 Apr;47(4):346-353. doi: 10.1080/00498254.2016.1187777. Epub 2016 Jun 9.

23.

Implications of Kidney Disease on Metabolic Reduction.

Alshogran OY, Nolin TD.

Curr Drug Metab. 2016;17(7):663-72. Review.

PMID:
27262337
24.

Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment.

Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, Nolin TD, Bihorac A; American Society of Nephrology Acute Kidney Injury Advisory Group.

Am J Kidney Dis. 2016 Jul;68(1):19-28. doi: 10.1053/j.ajkd.2015.12.033. Epub 2016 Mar 4.

25.

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM.

Clin Pharmacol Ther. 2016 Jul;100(1):75-87. doi: 10.1002/cpt.337. Epub 2016 Mar 7.

26.

Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup.

Mowry JB, Burdmann EA, Anseeuw K, Ayoub P, Ghannoum M, Hoffman RS, Lavergne V, Nolin TD, Gosselin S; EXTRIP Workgroup.

Clin Toxicol (Phila). 2016;54(2):103-14. doi: 10.3109/15563650.2015.1118488. Review.

PMID:
26795743
27.

Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Alshogran OY, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

J Chromatogr Sci. 2016 Apr;54(4):554-60. doi: 10.1093/chromsci/bmv186. Epub 2015 Dec 11.

28.

Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup.

Anseeuw K, Mowry JB, Burdmann EA, Ghannoum M, Hoffman RS, Gosselin S, Lavergne V, Nolin TD; EXTRIP Workgroup.

Am J Kidney Dis. 2016 Feb;67(2):187-97. doi: 10.1053/j.ajkd.2015.08.031. Epub 2015 Nov 11. Review.

29.

Bridging Translation by Improving Preclinical Study Design in AKI.

de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE Jr, Pullen N, Okusa MD, Faubel S; ASN AKI Advisory Group.

J Am Soc Nephrol. 2015 Dec;26(12):2905-16. doi: 10.1681/ASN.2015070832. Epub 2015 Nov 4. Review.

30.

Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease.

Alshogran OY, Urquhart BL, Nolin TD.

Drug Metab Lett. 2015;9(2):111-8.

PMID:
26282591
31.

Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.

Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS.

J Am Soc Nephrol. 2016 Jan;27(1):305-13. doi: 10.1681/ASN.2014111063. Epub 2015 Jul 30.

32.

Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Walsh DR, Nolin TD, Friedman PA.

Pharmacol Rev. 2015 Jul;67(3):656-80. doi: 10.1124/pr.115.010728. Review.

33.

Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.

Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS; EXTRIP Workgroup.

Ann Emerg Med. 2015 Aug;66(2):165-81. doi: 10.1016/j.annemergmed.2015.03.031. Epub 2015 May 15. Review.

PMID:
25986310
34.

Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.

Ghannoum M, Laliberté M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, Gosselin S; EXTRIP Workgroup.

Clin Toxicol (Phila). 2015 Jun;53(5):454-65. doi: 10.3109/15563650.2015.1035441. Review.

PMID:
25950372
35.

Drugs, Dialysis, Decisions, and Data: A Walk through the Minefield of Nephropharmacology.

Perry Wilson F, Nolin TD, Berns JS.

Semin Dial. 2015 Jul-Aug;28(4):323-4. doi: 10.1111/sdi.12390. Epub 2015 May 1. No abstract available.

PMID:
25929704
36.

[Drug pharmacokinetics in renal failure: What's new?].

Naud J, Dumayne C, Nolin TD, Leblond FA, Pichette V.

Nephrol Ther. 2015 Jun;11(3):144-51. doi: 10.1016/j.nephro.2014.12.006. Epub 2015 Apr 7. Review. French.

PMID:
25861715
37.

Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup.

Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M; Extracorporeal Treatments in Poisoning Workgroup.

Crit Care Med. 2015 Aug;43(8):1716-30. doi: 10.1097/CCM.0000000000001002. Review.

PMID:
25860205
38.

A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Nolin TD.

Semin Dial. 2015 Jul-Aug;28(4):325-9. doi: 10.1111/sdi.12374. Epub 2015 Apr 8. Review.

39.

Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine.

Ocque AJ, Stubbs JR, Nolin TD.

J Pharm Biomed Anal. 2015 May 10;109:128-35. doi: 10.1016/j.jpba.2015.02.040. Epub 2015 Feb 28.

PMID:
25767908
40.

Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup.

Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, Gosselin S, Nolin TD, Hoffman RS; EXTRIP workgroup.

Clin Toxicol (Phila). 2015 May;53(4):215-29. doi: 10.3109/15563650.2015.1014907. Epub 2015 Feb 26. Review.

PMID:
25715736
41.

Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, Lavergne V, Nolin TD, Ghannoum M; EXTRIP Workgroup.

Clin J Am Soc Nephrol. 2015 May 7;10(5):875-87. doi: 10.2215/CJN.10021014. Epub 2015 Jan 12. Review.

42.

Estimated GFR and cystatin C for drug dosing: moving beyond proof of concept to clinical translation?

Hudson JQ, Nolin TD.

Am J Kidney Dis. 2015 Apr;65(4):534-6. doi: 10.1053/j.ajkd.2014.11.006. Epub 2014 Dec 24. No abstract available.

PMID:
25542411
43.

Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.

Jang SM, Cardone KE, Nolin TD, Mason DL, Grabe DW.

BMC Nephrol. 2014 Dec 20;15:204. doi: 10.1186/1471-2369-15-204.

44.

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

Tortorici MA, Cutler DL, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K.

J Clin Pharmacol. 2015 Mar;55(3):241-50. doi: 10.1002/jcph.444. Epub 2015 Jan 14. Review.

PMID:
25501531
45.

Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement.

Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Lavergne V, Hoffman RS, Ghannoum M; EXTRIP Work Group.

Crit Care Med. 2015 Feb;43(2):461-72. doi: 10.1097/CCM.0000000000000708. Review.

PMID:
25493973
46.

Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM.

Am J Kidney Dis. 2015 May;65(5):701-9. doi: 10.1053/j.ajkd.2014.11.004. Epub 2014 Nov 25.

47.

Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL.

Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. Epub 2014 Nov 21.

PMID:
25453994
48.

Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Ghannoum M, Yates C, Galvao TF, Sowinski KM, Vo TH, Coogan A, Gosselin S, Lavergne V, Nolin TD, Hoffman RS; EXTRIP workgroup.

Clin Toxicol (Phila). 2014 Dec;52(10):993-1004. doi: 10.3109/15563650.2014.973572. Epub 2014 Oct 30. Review.

49.

Effect of experimental kidney disease on the functional expression of hepatic reductases.

Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

Drug Metab Dispos. 2015 Jan;43(1):100-6. doi: 10.1124/dmd.114.061150. Epub 2014 Oct 20.

PMID:
25332430
50.

Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.

Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL; Kidney Health Initiative.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):159-64. doi: 10.2215/CJN.05630614. Epub 2014 Sep 4.

Supplemental Content

Loading ...
Support Center